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Exploring the roles of HPV16 variants in head 
and neck squamous cell carcinoma: current 
challenges and opportunities
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Abstract 
The incidence of squamous cell carcinomas of the head and neck (HNSCC) is consistently increasing, in association 
with human papillomavirus (HPV) infection, especially HPV16. HPV variants show heterogeneity in the pathogenicity 
of cervical cancer, but little has been established about their relevance on HNSCC. This review addresses the distribu-
tion of HPV16 variants in HNSCC and their potential contribution to clinical practice. A search was performed in Pub-
Med using the keywords HNSCC HPV16 variants. Sixty articles were identified between 2000 and 2020 and 9 articles 
were selected for a systematic analysis. Clinical cohorts comprised 4 to 253 patients aged between 17 and 91 years 
with confirmed HPV16-positive HNSCC. Samples were collected from fresh biopsies of the tumour, oral rinse or formol 
fixed/paraffin embedded tissue, from the oral cavity, oropharynx, hypopharynx, larynx and Waldeyer’s tonsillar ring. 
HPV16 variants were identified using Sanger sequencing techniques. Seven studies addressed the HPV16 E6 gene, 
one studied E6 and E7, another studied L1 and one focused on the long control region. European variants repre-
sent 25–95%, Asian-American 5–57% and African 2–4% of the total isolates, suggesting a marked predominance of 
European strains. No correlations could be drawn with patient prognosis, partly because many studies relied on small 
patient cohorts. Additional studies are needed, particularly those employing next generation sequencing techniques 
(NGS), which will allow faster and accurate analysis of large numbers of samples.
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Background
Head and neck cancer is the sixth leading cancer by 
incidence worldwide [1] and comprises many different 
pathological entities. The diagnosis is often character-
ized by multifocal development and presentation at an 
advanced stage. [2] The age at diagnosis usually ranges 
between 50 and 70 years of age and men are significantly 
more likely to develop the disease than women (up to a 
4:1 proportion, depending on geographical localization) 
[3]. Currently, two major carcinogenic pathways leading 
to head and neck squamous cell carcinomas are recog-
nized: the first is associated with risk factors like smok-
ing and abusive alcohol consumption while the second is 
associated with human papillomavirus (HPV) infection 
[4, 5]. Over the past decade, several epidemiologic stud-
ies reported a 36.5% increase in the incidence of head and 
neck squamous cell carcinomas (HNSCC), particularly 
in high-income countries and among men < 60  years [4, 
6–8]. Available data indicates that these changes spe-
cifically involve oropharyngeal cancers [9, 10]. Although 
tobacco consumption has decreased, the incidence of 
HPV-positive oropharyngeal cancers has increased [11], 
indicating that HPV infection is the underlying cause 
for the overall increase in HNSCC incidence [12–14]. 
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Patients showing oral HPV infection are 53 times more 
likely to develop HNSCC [15]. Presently, HPV is present 
in approximately 35% of HNSCC and most HPV-positive 
cases emerge in lingual and palatine tonsils [16]. The 
presence of HPV DNA in tumour cells defines a specific 
pathologic entity within HNSCC with specific epidemi-
ology, molecular characteristics, and biological behav-
iour [17]. HPV interferes with key signaling pathways 
to promote carcinogenesis via its viral oncoproteins E6 
and E7, which lead to the inactivation of tumour protein 
53 (p53) and the retinoblastoma protein (pRB), respec-
tively [18]. HPV is a group of small, double-stranded 
DNA viruses that infect the epidermis and keratinizing 
mucosae. More than 100 HPV types have been identified 
[19, 20]. Presently, 40 different HPV types are known to 
infect mucosal epithelia and are categorized into low-risk 
and high-risk HPV types according to their epidemio-
logic association with cervical cancer [21]. In HNSCC, 
the majority of HPV types belong to this group includ-
ing HPV16, HPV18, HPV39 and HPV45 [22]. HPV16 is 
by far, the most detected type, accounting for 90% of all 
HPV-positive HNSCC cases [23], a significantly greater 
proportion than in cervical cancer where it accounts 
for little over 50% of cases [24]. Sequencing of the HPV 
genome also revealed intra-type variants with genetic dif-
ferences ranging between 0.5 and 1% [25, 26]. HPV vari-
ants arise mainly from nucleotide substitutions in some 
restricted positions in the genome coding region or in the 
noncoding region [27, 28]. The prevalence of variants for 
each HPV type varies significantly in different geographi-
cal areas [27]. Regarding HPV16, whole-genome analysis 
allowed the characterization of five distinct phylogenetic 
clusters named according to their original geographical 
distribution: European (E), Asian (As), Asian-American 
(AA), African 1 (Af1) and African 2 (Af2) [29–31]. Sub-
sequently, a new branch, North American 1 (NA1) was 
identified [32, 33]. Currently, emerging epidemiological, 
etiological, and molecular data suggest that intra-type 
HPV variants are biologically distinct and may be asso-
ciated with different risk of cervical cancer progression 
[28]. In vitro studies using 3D organotypic epithelial 
cell cultures showed that HPV16 E6 variants differ in 
their ability to abolish keratinocyte differentiation and 
to induce p53 degradation [34–36]. Those experimental 
results are corroborated by clinical studies on cervical 
cancer. The T350G (L83V) HPV16 variant is the most 
frequently found among invasive cervical cancers [21, 
37] and has been linked to a higher oncogenic potential 
than the prototype [38], possibly by facilitating persis-
tent viral infection, a critical factor for cancer develop-
ment [39–41]. Despite the growing number of studies 
concerning HPV16 variants on cervical cancer, there are 
currently very few reports describing their distribution 
in HNSCC and nothing is established about their impact 
on the development, treatment response and impact on 
disease outcome. Nonetheless, HPV16 variants may also 
play an important role in head and neck carcinogenesis 
and studying their impact is needed due to the rising 
incidence of HPV-positive HNSCC [18, 23, 25, 42]. The 
purpose of this work is to systematically review the dis-
tribution of HPV16 variants in HNSCC and to assess the 
available knowledge concerning their potential contribu-




A systematic review was performed on the PubMed elec-
tronic database (https:// pubmed. ncbi. nlm. nih. gov) using 
the following keywords search criteria: HNSCC HPV16 
variants. Observational studies reporting the distribution 
of HPV16 variants in HNSCC and published between 
2000 and 2020 were included. Review articles, case 
reports and articles dealing with other types of cancer 
were excluded (Fig. 1). The selection search criteria were 
based on tumour localization, nature of sample and back-
ground of the variant study field. The studies were inde-
pendently assessed to identify the prevalence of HPV16 
variants in HNSCC and evaluate in respective cohorts for 
correlation with clinicopathological parameters. HNSCC 
Fig. 1 Analytical flow for systematically reviewing published articles 
dealing with HPV16 variants in HNSCC
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patients were categorized into different sites (oral cavity 
and oropharynx) and further into sub cohorts based on 
the demographic and clinical information provided. The 
published data were summarized using frequencies and 
percentages for HPV16 variants, stratified by tumour 
location, types of tumour samples, patient cohort size, 
sequencing methodology, and clinical variables such as 
age and gender (Fig. 2.)
General findings
From 61 records found using the search criteria HNSCC 
HPV16 DNA cell carcinoma variants frequency patients’ 
cohorts, we selected 9 studies while 52 studies were 
excluded from further analysis, including review arti-
cles and papers which fit the exclusion criteria (Fig.  1). 
Selected articles report data from a total of 945 patients 
in the period between 2000 and 2020, distributed by 6 
countries. (Table  1) Three studies were performed in 
Europe, three  in the USA, two in Asia and Middle East 
(Japan and Iran) and one in South America (Brazil). 
HPV16 variants were evaluated in nine different clini-
cal cohorts. All studies were different and did not con-
tain the evaluation of the same cases. Overall, the study 
population consisted of patients whose age at diagnosis 
ranged between 17 and 91 years. The gender ratio was 1:3 
or 1:4 (female to male), and all cases were histologically 
confirmed as HNSCC. The specimens used to evaluate 
HPV16 were primary tumours located in the oral cav-
ity, oropharynx, hypopharynx, larynx and Waldeyer’s 
tonsillar ring. Regional lymph node metastases were also 
included in one study. The samples used to analyze were 
diverse and consisted of fresh tissue, oral rinse, or forma-
lin fixed/paraffin embedded tissue.
The use of the p16INK4a marker is to clinically detect 
an oncogenically active HPV infection and is considered 
as a surrogate marker for HPV infection [43, 44]. From 
the 9 studies evaluated three described the expression 
pattern of p16INK4a among negative HNSCC HPV(−) 
and HNSCC HPV16 cases. For all studies there was a 
significant difference in p16INK4a expression between 
HNSCC HPV(−) and HNSCC HPV16(+). Pakdel et  al. 
2020 observed the expression of p16INK4a among HPV 
variants and showed that a strong p16INK4a expres-
sion was present in poorly differentiated tumour tissues 
infected with HPV16 sublineage A2 [45].
HPV detection and genotyping
HPV was detected using PCR-based techniques 
employing consensus degenerate primers: MY09/11 (4 
studies) MY09/11 and/or GP05/06 (2 studies), PGMY 
(one study) and SPF1/2 (one study); all of which are 
complementary to the conserved L1 region. One study 
detected HPV using in  situ hybridization. HPV geno-
typing was performed using different methods. Two 
studies using a commercial kit (INNO LIPA) which 
identifies 28 different HPV types (6, 11, 16, 18, 26, 31, 
33, 35, 39, 40, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 
69, 70, 71, 73, 74, 82) by reverse blot hybridization. Two 
other studies used TaqMan PCR methods targeting the 
E6 or E6/LCR. One study used restriction fragment 
length polymorphism (RFLP) analysis. Two studies per-
formed direct Sanger sequencing of the PCR products. 
The HPV frequency in the different cohorts ranged 
from 10 to 100% of the cases, and the HPV16 distri-
bution ranged between 67 and 100% of all HPV posi-
tive cases (Table  1). Except the study done in 2020 in 
Fig. 2 Analytical variables flow for included articles dealing with HPV16 variants in HNSCC search criteria





































































































































































































































































































































































































































































































































































































































Page 5 of 9Cochicho et al. Virol J          (2021) 18:217  
Iran, where just 16% of the HPV detected were HPV16. 
The most common HPV in their series was HPV16 but 
also followed by HPV18 and HPV11 and the cases were 
almost located in Oral cavity and Larynx; only 6 tonsils 
in all 108 cases were evaluated, explaining the low HPV 
frequency overall.
Identification HPV16 variants
Of the 9 studies, seven studies identified HPV16 vari-
ants by sequencing the E6 gene, one addressed variants 
in the L1 gene and another the long control region. In 
one study the E7 gene was also sequenced along with 
E6 (Table 1). In all studies, the identification of HPV16 
variants was performed by Sanger sequencing tech-
niques and by comparison to the reference sequence 
(prototype). Next generation sequencing (NGS) was 
not used in any of the studies evaluated. However, the 
reliance on conventional Sanger sequencing is likely 
to limit the number of cases that can be analyzed and 
the reliability of results. [26, 46, 47] Sanger sequenc-
ing techniques show limitations concerning the size of 
amplicons, which may compromise the assay sensitiv-
ity. Additionally, to overcome polymerase errors and 
guarantee the integrity and robustness of the results, 
it is necessary to perform replicates for each case or 
vector molecular assays [48]. Such replicates add sig-
nificantly to the workload and costs and constitute 
a limitation to analyze large patient cohorts. In fact, 
only two out of nine studies included over 200 HNSCC 
patients and none analyzed more than 52 HPV-positive 
patients for HPV16 variants. Future studies aiming to 
study larger patient cohorts are likely to benefit from 
NGS techniques, which provide faster and reliable 
sequencing results of larger amplicons [25, 26, 46].
Prevalence of HPV16 variants
The frequency of each HPV16 variant (E, NA, AF, AS and 
AA) was estimated for each of the 9 studies included in 
the systematic review (Table  2). Gillison et  al. [37] first 
reported data concerning the distribution of HPV16 E6 
variants in HNSCC. The authors evaluated 52 HPV16-
positive patients from an overall HNSCC cohort com-
prising 259 patients. The age at diagnosis ranged between 
17 and 91  years-old (median, 63  years-old) and the 
majority were smokers, with or without alcohol con-
sumption (87%). Tumours were localized in the naso-
pharynx (n = 2), oral cavity (n = 84), oropharynx (n = 60), 
hypopharynx (n = 21), larynx (n = 86). HPV-positive 
patients showed significantly improved disease outcomes 
compared with HPV-negative patients. All samples used 
were HNSCC fresh tumour specimens. The HPV16 vari-
ants were classified into the same phylogenetic group as 
the European prototype in 75% of cases, Asian in 17%, 
North American in 4.0% and African 1 in 4.0% of cases. 
Six novel variants not previously reported (E-G315T, 
E-G315G, E-C395G, E-A478T, E-A132T, Af1-C311, 
Af1-A389) were also identified. The authors remarked 
that the distribution of variants in HNSCC resembled 
that observed in cervical cancer. However, no conclu-
sions were drawn concerning the potential contribu-
tion of specific HPV16 E6 variants for increasing cancer 
risk or modifying tumour biopathology and prognosis. 
Four years later, Hoffmann et  al. [38] identified HPV16 
variants in 7 out of 21 tumour specimens of HNSCC. 
The authors analyzed the E6 and E7 ORFs. Altogether, 
the DNA samples carried HPV16 prototype European 
Table 2 Frequency of HPV16 variants
(–) not evaluated; AA Asia-American HPV16 Variant; AF African HPV16 Variant; AS Asian HPV16 variant; E European HPV16 variant; E6 HPV Early protein 6; E7 HPV Early 
protein 7; LCR long control region; L1 late gene; NA North American HPV16 Variant









European (E) North 
American




E-350-G (n) (NA) (n) (AF1|AF2) (n) (AS) (n) (AA) (n)
[48] 56 52 E6 39 6 2 2 9 0
[49] 24 21 E6 E7 15 8 0 0 0 0
[50] 14 13 L1 9 0 1 2 0 1
[51] 44 19 E6 18 4 0 0 1 0
[52] 8 8 E6 5 5 0 0 0 0
[53] 4 4 E6 2 1 0 0 0 2
[54] 10 10 E6 8 8 0 0 0 0
[55] 25 21 LCR 9 – 0 0 0 12
[56] 17 13 E6 11 – 0 0 0 2
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variant (29%), the European variant T350G (38%) and 
33% Euro-German variant (A131G + C712A). Again, 
no conclusions could be drawn concerning the clinical-
pathological relevance of the HPV16 variants identified, 
partly because of the cohort’s small size. Badaracco et al. 
[49], published molecular analysis data on the HPV16 L1 
ORF, from an Italian cohort (total n = 115, of which only 
13 were tested for HPV variants), composed of 86 men 
and 29 women, with a mean age of 63.21 years old. A high 
percentage of patients were smokers (67%) and alcohol 
drinkers 43%. Tumours were localized mostly in the oral 
cavity (n = 60), followed by the larynx (n = 30), the oro-
pharynx (n = 10), the tonsil area (n = 8), the hypophar-
ynx (n = 5) and the sinus/nose (n = 2). In this study, the 
presence of HPV was not significantly associated with 
disease-free survival at 2 years. Sixty nine percent of the 
cases (13 cases) analyzed showed European-German 
variants (9 cases), 15% were African type 2 (2 cases), 
8% Asian-American (1 case), and the remaining 8% (1 
case) had an unclassified variant. The predominance 
of the European variant was unsurprising considering 
the Italian origin of the patients. No correlations were 
drawn between the presence of HPV16 variants and any 
epidemiological, pathological, or clinical data. Agrwal 
et al. [50], studied 19 HPV16 isolates from a universe of 
135 HNSCC samples. The median age at diagnosis was 
57 years-old, 77% of the patients were men, most patients 
had a history of smoking (n = 62 smokers versus 51 non-
smokers) but were non-drinkers (73 non-drinkers versus 
41 drinkers). All analyzed cases showed European vari-
ants and a single case carried an Asian variant. The most 
common European variant was E-350 T (n = 6), followed 
by E-350G (n = 4) and E-T131G (n = 2). Importantly, 
eight of the 19 isolates contained European variants 
with sequences unique to a single individual. Boscolo-
Rizzo et  al. [51] analyzed HPV E6 variants in a short 
(n = 8) case series. The authors showed the presence of 
the T350G mutation in 5 cases located in the oral cav-
ity and oropharynx, while three tumours located in the 
larynx and hypopharynx contained HPV 16 prototype 
sequences. Joseph et  al. [52] compared HPV16 variants 
present in four patients with bilateral tonsillar HNSCC. 
Two cases carried European variants while two others 
carried Asian-American variants. The results show that, 
in all 4 patients, the same HPV16 variant was present in 
the bilateral tumours, supporting the hypothesis that a 
single HPV infection, rather than independent infections 
with distinct agents, is responsible for those bilateral 
tumours. Hassani et al. [53] studied the HPV16 variants 
present in 10 cases of tonsillar HNSCC. The authors 
found that the E-350G-variant was present in 80% of 
cases while the European prototype was identified in the 
other 20%. Again, this short case series did not provide 
data concerning the pathobiological relevance of HPV16 
variants. In the following year, Betiol et al. [54] reported 
the distribution of HPV16 variants in a Brazilian cohort 
of 21 HNSCC patients. The authors analyzed the HPV16 
LCR and found that 12 (57.1%) patients carried Euro-
pean and 9 carried Asian-American (42.9%) variants. 
The authors remarked that the slight predominance of 
European variants accompanied observation from their 
normal cervical samples, suggesting that the distribu-
tion of HPV16 variants reflects the overall frequency in 
each studied population. The most recent study was pub-
lished by Pakdel et al. [45]. Thirteen HNSCC tissue speci-
mens tested positive for HPV16 using overlapping PCR 
assays and were analyzed for the presence of E6 variants. 
There was a marked predominance of European variants 
(84.6%) followed by Asian-American (15.4%) variants.
Discussion
We reviewed the published literature on HPV16 variants 
in HNSCC, aiming to evaluate the biological meaning 
of those variants in this particular location. The clini-
cal management of HNSCC improved greatly since the 
recognition of HPV-positive and HPV-negative lesions. 
Although tumour recurrence still occurs in 10–20% of 
HPV-positive HNSCC patients, the majority of these 
patients clearly benefit from therapeutic de-escalation 
[55]. The lack of adequate biomarkers to define more tai-
lored approaches is still necessary in SCC HPV associ-
ated tumours [56]. The large majority of these tumours 
are associated with HPV16 and a deeper understanding 
of the bio pathological implications of distinct HPV16 
variants would contribute to the molecular characteri-
zation of HPV-positive HNSCC and may help to define 
patient’s subgroups that would benefit from specific ther-
apeutic approaches. Data from cervical cancer patients 
showed an association between the presence of non-
European HPV16 lineages, a longer viral persistence [57, 
58] and an increased risk of developing high-grade cervi-
cal intraepithelial neoplasia [59]. Apparently, within indi-
viduals, HPV genomes harbour high levels of variability 
in HPV16 genome sequence upon normal to pre-cancer/
cancer [60] revealing several fundamental discoveries 
and suggesting a paradigm shift from HPV16 as a single 
viral entity to theorize each HPV16 isolated to be a sepa-
rate virus with distinct carcinogenic potential [61]. This 
would imply that within HPV16, the genetic variation 
partly predicts the risk of pre-cancer and cancer [62]. In 
particular, specific sublineages (A4, C, D2, and D3) have 
shown a significantly increased risk compared to the 
most common A1/A2 sublineages [26] and assured D2, 
for the strongest risk of cancer within glandular epithe-
lium (adenocarcinomas) [26].
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The major data from whole-sequences obtained from 
individual clinical specimens agrees that the genetic vari-
ation occurs more commonly on low-grade or benign 
HPV16 infections [61] and corrected explained In 
case–control analyses describing the highest amino acid 
changing variants HPV16 in the controls throughout the 
genome with cervix cancer. [62] Therefore, E7 oncogene 
lacks nonsynonymous (amino acid changing) variants in 
cervical cancers, suggesting the E7 conservation is admit-
ted for carcinogenicity. [61] The specific conservation of 
the 98 amino acids of E7, that directly disrupts Rb func-
tion, was shown to be crucial for trigger carcinogenesis, 
owing to be commented as a highly specific target for 
etiologic and therapeutic research [26].
Presenting data from a cohort study that compares 
genomic characteristics of HPV associated with cervi-
cal versus oropharyngeal tumours using DNA sequence 
analysis showed no significant differences between dis-
tribution in HPV16 variants [24], both presenting major 
prevalence of the European variant. Instead, the HPV 
E6 gene amplified from oropharyngeal samples reported 
over more nonsynonymous mutations, but also for the 
E7 gene, no differences were found in mutation rates 
between the two anatomical locations [24, 62]. Notably, 
the E7 gene is conserved in both locations corroborating 
the recent findings on cervical cancer studies. The appar-
ent restriction on E7 mutations seems to be present in 
the oropharynx, as well. Indeed, described all both share 
common biological features, but the important differ-
ences present in HPV-genome may explain their distinct 
pathophysiological mechanisms and susceptibility to 
treatment. Nevertheless, the invariability of E7 presents 
an attractive potential target for therapy at both loca-
tions. [24]
In all the studies evaluated in this analysis, the most 
prevalent variant was the European Variant, which 
belongs to the European lineage and within this line-
age the E-350-G HPV16 variant was the most frequent 
in majority of the studies sequencing based E6 and/or 
E7 regions with 29% and 53% respectively, although the 
cohorts had or not an European origin, (cohorts were 
from Brazil, United States of America, Japan, Italy and 
Germany (Table 3).
As it was established from molecular analysis stud-
ies in cervical cancer, that the European variant T350G, 
was the variant frequently found in cervical intraepi-
thelial neoplasms and cancers, and has been associated 
with progression to cervical cancer particularly in North 
European women. The detection of the T350G variant in 
a large proportion of HNSCC patients, therefore, indi-
cates that this variant might also play an important role 
in HN carcinogenesis. Hassani et  al.in 2015 supported 
this hypothesis, elucidating that the HPV-16 E-350G 
variant has a polymorphism in residue 83, a leucine for 
valine (L83V), probably responsible for the increased 
cancer risk [53].
Conclusions
In HNSCC different lineages of HPV16 variants can 
be identified and differ geographically. Although most 
reviews described only the distribution of HPV16 vari-
ants in HNSCC, LeConte in a more detailed analysis of 
those studies found important differences. They found 
the distribution of two HPV16 variant groups differ sig-
nificantly in oropharyngeal cancer and cervical cancer. 
The European + South America (E + AS) variant groups 
showed a higher prevalence in the oropharyngeal sam-
ples, representing 90.2%, than in cervical carcinomas 
(71.4%). Moreover, the Asia-American (AA1 + AA2) var-
iant groups were present in 22.5% of cervical cancers in 
contrast to 4.4% in the oropharyngeal cancers [24]. The 
number of cases studied does not allow us to explore the 
importance of those differences nor to understand the 
potential role determining the clinical behaviour and 
potential use to select treatment and prognosis. Hope-
fully, the new sequencing era will enrich the study of 
HPV and related cancers. The advances in HPV whole-
genome sequencing [46] provided technically achievable 
large-scale longitudinal studies on HPV whole-genomic 
sequences and promotes an exhaustive understanding of 
Table 3 Frequency HPV16 Variants by region genome location
 (–) not evaluated; AA Asia-American HPV16 Variant; AF African HPV16 Variant; AS Asian HPV16 Variant; E European HPV16 variant; E6 HPV Early protein 6; E7 HPV Early 













Asian (AS) Asia 
American 
(AA)All lineages E-350-G
[50] 115 115 L1 69% Not Detected - 15% - 8%
[48, 51–54, 56] 621 106 E6 78% 29% 2% 2% 9% 4%
[49] 24 21 E6E7 71% 53% - - - -
[55] 205 21 LCR 42.8% - - - - 57.2%
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the viral genetic diversity within and between infected 
individuals and will make the link between variants and 
cancer risk, comprehensively [46, 61].
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